Momin et al. built upon this knowledge in their study by developing an antibody–siRNA conjugate (ARC) specifically designed to target and silence Spp1 in TREM2+ cardiac macrophages as a novel immunotherapy for the treatment of atrial fibrillation (AFib) [58]. Here, TREM2 is linked to atrial fibrillation.